However, the poor prognosis of patients expressing high levels of BST2 is likely due to platinum resistance, and not to increased NPC cell proliferation or radiation resistance, because BST2 expression level was only associated with prognosis in patients who received >3 cycles of platinum-based chemotherapy and not in patients who received fewer cycles when they received similar doses of radiation. The gene discussed is BST2; the disease is nasopharyngeal carcinoma.